Page 96 - 2019_08-Haematologica-web

J-C. Ianotto et al.
Hematol Oncol. 2009;31(9):678-680.
36. Lackner H, Urban C, Benesch M, et al. Long- term use of anagrelide in the treatment of children with essential thrombocythemia. Eur J Haematol. 2006;77(4):358-359.
37. Langabeer SE, Haslam K, McMahon C. A prenatal origin of childhood essential throm- bocythemia. Br J Haematol. 2013;163(5): 676-678.
38. Bertrand A, Heissat S, Caron N, et al. Deep vein thrombosis revealing myeloprolifera- tive neoplasm in two adolescents. Arch Ped. 2014;21(5):497-500.
39. Pulini S, D'Amico E, Basilico R, et al. Portal venous thrombosis in a young patient with idiopathic myelofibrosis and intrahepatic extramedullary hematopoiesis: a difficult diagnosis, prognosis and management. Leukemia. 2007;21(11):2373-2375.
40. Robins EB, Niazi M. Essential thrombo- cythemia in a child with elevated throm- bopoietin concentrations and skeletal anom- alies. Pediatr Blood Cancer. 2008;50(4):859- 861.
41. Roy NB, Treacy M, Kench P. Childhood essential thrombocythemia. Br J Haematol. 2005;129(5):567.
42. Scherer S, Ferrari R, Rister M. Treatment of essential thrombocythemia in childhood. Pediatr Hematol Oncol. 2003;20(5):361-365.
43. Singh A, Nityanand S, Sonker A, Kumar S. Successful use of the cell separator Hemonetics multicomponent collection sys- tem+ for therapeutic thrombocytapheresis in a low body weight child of essential thrombocythemia. Asian J Transfus Sci. 2015;9(2):207-209.
44. Slone JS, Smith MC, Seegmiller AC, Sidonio RF, Yang E. Idiopathic myelofibrosis in chil- dren: primary myelofibrosis, essential thrombocythemia, or transient process? J Pediatr Hematol Oncol. 2013;35(7):559-565.
45. Szegedi I, Benko I, Mero G, Prinzinger A, Kappelmayer J, Kiss C. Long-lasting partial remission by interferon-alpha treatment in a child with essential thrombocythemia. Pediatr Blood Cancer. 2007;49(5):744-747.
46. Tokgoz H, Caliskan U, Yüksekkaya HA, Kucukkaya R. Essential thrombocythemia with Mpl W515K mutation in a child pre- senting with Budd-Chiari syndrome. Platelets. 2015;26(8):805-808.
47. Vafaie M, Jaseb K, Ghanavat M, Pedram M, Rahiminia T. Asymtomatic [sic] essential thrombocythemia in a child: a rare case report. Int J Hematol Oncol Stem Cell Res. 2013;7(2):35-37.
48. Wigton JC, Tersak JM. JAK2+ Essential Thrombocythemia in a young girl with Budd-Chiari syndrome: diagnostic and ther- apeutic considerations when adult disease strikes the young. J Pediatr Hematol Oncol.
2016;38(1):70-73.
49. Benedik-Dolni ar M, Homan M, Brecelj J.
JAK2V617F mutation in a 9-year-old girl with polycythemia vera and Budd-Chiari syndrome: a case report. J Pediatr Hematol Oncol. 2012;34(3):243-244.
50. Berman JN, Greer WL, Archambeault S, et al. JAK2 V617F positive polycythemia vera in a child with neurofibromatosis type I. Pediatr Blood Cancer. 2008;51(5):689-691.
51. Braconnier O, Monpoux F, Affanetti M, Bérard E, Sirvent N. [Polycythemia vera and JAK-2 mutation in childhood: a case report]. Arch Pediatr. 2007;14(10):1202-1205.
52. Coskun ME, Height S, Dhawan A, Hadzic N. Ruxolitinib treatment in an infant with JAK2+ polycythemia vera-associated Budd- Chiari syndrome. BMJ Case Rep. 2017;2017.
53. Goldstein G, Maor J, Kleinbaum Y, Palumbo M, Sidi Y, Salomon O. Budd-Chiari syn- drome in very young adult patients with polycythemia vera: report of case series with good outcome with direct thrombin inhibitor treatment. Blood Coagul Fibrinolysis. 2013;24(8):848-853.
54. Guo HX, Chan GC, Chiang AK, Ho MH, Chan EY, Ha SY. Dural sinus thrombosis owing to polycythemia vera in a 12-year-old girl. Paediatr Int Child Health. 2012;32 (3):167-170.
56. Park MJ, Shimada A, Asada H, Koike K, Tsuchida M, Hayashi Y. JAK2 mutation in a boy with polycythemia vera, but not in other pediatric hematologic disorders. Leukemia. 2006;20(8):1453-1454.
57. Osgood EE. Polycythemia vera: age relation- ships and survival. Blood. 1965;26:243-256.
58. Reid MM, Saunders PW, Kernahan J. Myeloproliferative disease in children: a demographic study. J Clin Pathol. 1988;41 (8):883-885.
59. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol. 1997;15(4):173-189.
60. Hasle H. Incidence of essential thrombo- cythemia in children. Br J Haematol. 2000; 110(3):751.
61. Visser O, Trama A, Maynadié M, et al; RARECARE Working Group. Incidence, sur- vival and prevalence of myeloid malignan- cies in Europe. Eur J Cancer. 2012;48(17): 3257-3266.
62. Horibe K, Saito AM, Takimoto T, et al. Incidence and survival rates of hematological malignancies in Japanese children and adoles- cents (2006-2010): based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol. 2013;98(1):74-88.
63. Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-
analysis. Am J Hematol. 2014;89(6):581-587. 64. Rumi E, Cazzola M. Diagnosis, risk stratifi- cation, and response evaluation in classical myeloproliferative neoplasms. Blood.
2017;129(6):680-692.
65. Vannucchi AM, Lasho TL, Guglielmelli P, et
al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861- 1869.
66. Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21-30.
67. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J. 2018;8(1):3.
68. Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018;8(1):2.
69. Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016;175(1):31-36.
70. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
71. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloprolifera- tive neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
72. Lussana F, Carobbio A, Randi ML, et al. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythemia vera. Br J Haematol. 2014;167(4):541-546.
73. Landolfi R, Marchioli R, Kutti J, et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350 (2):114-124.
74. Alvarez-Larrán A, Pereira A, Guglielmelli P, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016;101 (8):926-931.
75. Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye's syn- drome in the United States from 1981 through 1997. N Engl J Med. 1999;340 (18):1377-1382.
76. Bennett MJ, Russell LK, Tokunaga C, et al. Reye-like syndrome resulting from novel missense mutations in mitochondrial medi- um- and short-chain l-3-hydroxy-acyl-CoA dehydrogenase. Mol Genet Metab. 2006;89(1-2):74-79.
77. McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol. 2011;18(3):158-165.
1588
haematologica | 2019; 104(8)